First Final Written Decision in Inter Partes Review of Pharmaceutical Related Patents
Client Alert | 2 min read | 06.27.14
On June 20, 2014, the U.S. Patent and Trademark Office's Trial and Appeal Board, for the first time, rendered final written decisions in inter partes review proceedings of pharmaceutical related patents, specifically claims covering compositions for and methods of making and using folate-containing dietary supplements said to address elevated levels of homocysteine in the blood that can lead to cardiovascular, ocular, neurological and skeletal diseases. Since the inter partes review procedure went into effect in September 2012, more than 1350 patent challenges have been initiated, more than 700 trials instituted, and more than 65 final written decisions issued, but these are the first final written decisions in cases involving pharmaceutical related patents. Of particular significance, the Board found all of the challenged patent claims it reviewed to be unpatentable.
The petitions in the four inter partes review proceedings (IPR 2013-00116; IPR 2013-00117; IPR 2013-00118; and IPR 2013-00119) were filed by Gnosis SpA, which had been sued by Merck in the Eastern District of Texas for infringement of certain claims of the four challenged patents. Merck is a licensee of three of the patents, which are owned by South Alabama Medical Science Foundation. The fourth patent is owned by Merck's subsidiary, Merck & Cie. The district court case was stayed pending the inter partes review proceedings.
The Board determined that all of the challenged claims on which it rendered a decision were unpatentable as obvious, with certain of the claims also being unpatentable as anticipated. In each of the four proceedings, the Board determined that the patent owners did not persuasively show a nexus between the asserted objective evidence of nonobviousness and the claims under review. The Board concluded that, on balance, Gnosis's strong evidence of obviousness outweighed the patent owner's objective evidence of non-obviousness, and a preponderance of the evidence supported the findings of unpatentability.
Multiple expert declarations were submitted by both sides in each of the proceedings. In each of the cases, aside from amending the patents to cancel certain challenged claims, the patent owner did not otherwise attempt to substantively amend any of the claims.
The patent owners now have the ability to either file Requests for Reconsideration or to file appeals to the Federal Circuit.
Contacts
Insights
Client Alert | 3 min read | 09.15.25
On August 19, 2025, the U.S. Senate Committee on Finance (“Senate Finance Committee”) sent Paul Atkins, Chairman, U.S. Securities and Exchange Commission (“SEC”) a letter calling on the SEC to investigate White River Energy Corp (“White River”). In the letter, the Senate Finance Committee confirmed a criminal investigation into White River related to the sale of so-called “tribal tax credits” that according to both Congress and the IRS, do not exist. The letter further states that White River allegedly earned millions of dollars selling these credits and has not been forthcoming with investors regarding the existence of the criminal investigation. According to the Senate Finance Committee, White River has failed to file financial disclosure documents with the SEC since March 15, 2024, missing six consecutive reporting periods. The letter instructs White River to disclose the existence of the DOJ criminal tax investigation, and calls on the SEC to take action if White River fails to do so.
Client Alert | 4 min read | 09.12.25
SBA’s OHA Further Defines Extraordinary Action in SDVOSB Appeal
Client Alert | 6 min read | 09.11.25
U.S. Department of Commerce Partially Relaxes Export Controls on Syria
Client Alert | 9 min read | 09.11.25
